Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Enliven Therapeutics, Inc.
Report date February 12, 2026 · Filed February 18, 2026
Section 16 reporting ended · disclosed 2026-02-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2026-02-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 20,000 · Balance 20,000 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.16 · Expires 2036-02-12 | Direct | 120,000 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Grant · Acquired 120,000 · Balance 120,000 F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 215,011 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 215,011 F2: The shares are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2: The shares are held by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee.
F3: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 18, 2026 00:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001967163-26-000002 · form4-02182026_120233.xml · derivative · entry 3 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-02-12 F3 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:53 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001967163-26-000002 · form4-02182026_120233.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 22:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 243 | $28.50 | $6,925.50 |
DisclosureSEC source: 0001967163-26-000001 · form4-01132026_100110.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 215,011 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 22:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 48,057 | $27.98 | $1,344,836.70 |
DisclosureSEC source: 0001967163-26-000001 · form4-01132026_100110.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 215,254 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,705 | $21.78 | $37,133.88 |
DisclosureSEC source: 0001967163-25-000005 · form4-12102025_101217.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 263,311 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $21.51 to $22.055. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:13 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,958 | $20.76 | $102,938.99 |
DisclosureSEC source: 0001967163-25-000005 · form4-12102025_101217.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 265,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $20.51 to $21.495. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 613 | $17.94 | $10,995.44 |
DisclosureSEC source: 0001967163-25-000004 · form4-11122025_101156.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 269,974 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $17.835 to $18.265. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 22:34 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,054 | $17.35 | $105,038.72 |
DisclosureSEC source: 0001967163-25-000004 · form4-11122025_101156.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 270,587 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $16.825 to $17.8248. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 21:21 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,667 | $20.10 | $133,992.70 |
DisclosureSEC source: 0001967163-25-000003 · form4-10092025_091058.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 276,641 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $20.0001 to $20.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| September 08, 2025 Filed Sep 11, 2025 00:12 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,667 | $20.24 | $134,957.41 |
DisclosureSEC source: 0001415889-25-024196 · form4-09112025_120931.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 283,308 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $19.915 to $20.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:51 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 405 | $18.93 | $7,666.53 |
DisclosureSEC source: 0001415889-25-021456 · form4-08112025_100829.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 289,975 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $18.805 to $19.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 22:51 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,262 | $18.20 | $113,948.99 |
DisclosureSEC source: 0001415889-25-021456 · form4-08112025_100829.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 290,380 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $17.78 to $18.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 23:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 305 | $20.69 | $6,311.91 |
DisclosureSEC source: 0001415889-25-019609 · form4-07092025_110738.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 296,642 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $20.58 to $20.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 23:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,362 | $19.75 | $125,638.68 |
DisclosureSEC source: 0001415889-25-019609 · form4-07092025_110738.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 296,947 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $19.46 to $20.175. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 22:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 60 | $21.16 | $1,269.60 |
DisclosureSEC source: 0001415889-25-016734 · form4-06112025_100610.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 303,309 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 22:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,607 | $20.33 | $134,304.45 |
DisclosureSEC source: 0001415889-25-016734 · form4-06112025_100610.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 303,369 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $19.96 to $20.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:48 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 104 | $19.87 | $2,066.68 |
DisclosureSEC source: 0001415889-25-012591 · form4-05092025_100535.xml · nonDerivative · entry 3 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 309,976 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $19.80 to $19.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:48 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 390 | $19.40 | $7,565.42 |
DisclosureSEC source: 0001415889-25-012591 · form4-05092025_100535.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 310,080 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $18.7902 to $19.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| May 07, 2025 Filed May 9, 2025 22:48 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,173 | $18.30 | $112,946.76 |
DisclosureSEC source: 0001415889-25-012591 · form4-05092025_100535.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 310,470 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $17.7781 to $18.7623. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 148 | $19.27 | $2,852.27 |
DisclosureSEC source: 0001415889-25-010474 · form4-04092025_080436.xml · nonDerivative · entry 3 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 316,643 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F5 · price: This transaction was executed in multiple trades at prices ranging from $18.995 to $19.4361. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,763 | $18.29 | $50,526.98 |
DisclosureSEC source: 0001415889-25-010474 · form4-04092025_080436.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 316,791 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $17.995 to $18.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 3,756 | $17.81 | $66,889.48 |
DisclosureSEC source: 0001415889-25-010474 · form4-04092025_080436.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 319,554 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $16.985 to $17.975. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,667 | $21.44 | $142,936.48 |
DisclosureSEC source: 0001415889-25-007683 · form4-03112025_090341.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 323,310 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $20.99 to $22.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 22:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,667 | $21.93 | $146,205.98 |
DisclosureSEC source: 0001415889-25-003515 · form4-02102025_100202.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 329,977 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $21.655 to $22.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:32 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 171,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003515 · form4-02102025_100202.xml · derivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 171,000 shares Expires 2035-02-06 F4 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · derivative · entry 10 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,342 Underlying: Common Stock · 9,000 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F8 · derivative.exercise_date: The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on January 14, 2021. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · derivative · entry 9 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 827 Underlying: Common Stock · 2,000 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,700 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · derivative · entry 8 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67 Underlying: Common Stock · 10,700 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F7 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 90 | $24.60 | $2,214.07 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 7 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 336,644 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F6 · price: This transaction was executed in multiple trades at prices ranging from $24.60 to $24.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 6,577 | $24.17 | $158,956.88 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 6 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 336,734 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $23.595 to $24.585. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5 · ownership.nature: The shares are held by The Patel / Dong Family Trust. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,440 | $24.56 | $35,367.84 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 5 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F3 · price: This transaction was executed in multiple trades at prices ranging from $24.54 to $24.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 20,260 | $24.15 | $489,329.65 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 4 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,440 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $23.5364 to $24.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 9,000 | $2.48 | $22,320.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 3 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 2,000 | $2.48 | $4,960.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 10,700 | $1.12 | $11,984.00 |
DisclosureSEC source: 0001415889-25-001301 · form4-01102025_100148.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:23 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 716 | $30.00 | $21,482.51 |
DisclosureSEC source: 0001415889-24-025505 · form4-10222024_081006.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 343,311 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee. Read SEC document |
| July 16, 2024 Filed Jul 16, 2024 21:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,547 | $25.01 | $38,692.17 |
DisclosureSEC source: 0001415889-24-019600 · form4-07162024_090759.xml · nonDerivative · entry 3 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 344,027 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.07. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 21:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 30,978 | $25.05 | $776,039.17 |
DisclosureSEC source: 0001415889-24-019600 · form4-07162024_090759.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 345,574 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 21:37 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 17,475 | $25.07 | $438,094.76 |
DisclosureSEC source: 0001415889-24-019600 · form4-07162024_090759.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 376,552 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held by The Patel / Dong Family Trust Dated August 24 2017 for which the Reporting Person serves as trustee. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,133 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-016279 · form4-06102024_100635.xml · derivative · entry 4 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,342 Underlying: Common Stock · 1,133 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · derivative.exercise_date: The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on January 14, 2021. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,133 | $20.06 | $22,722.43 |
DisclosureSEC source: 0001415889-24-016279 · form4-06102024_100635.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.785 to $20.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,133 | $2.48 | $2,809.84 |
DisclosureSEC source: 0001415889-24-016279 · form4-06102024_100635.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,107 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-013383 · form4-05162024_110525.xml · derivative · entry 4 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,475 Underlying: Common Stock · 1,107 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F3 · derivative.exercise_date: The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on January 14, 2021. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,107 | $25.00 | $27,675.00 |
DisclosureSEC source: 0001415889-24-013383 · form4-05162024_110525.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:29 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 1,107 | $2.48 | $2,745.36 |
DisclosureSEC source: 0001415889-24-013383 · form4-05162024_110525.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| May 09, 2024 Filed May 13, 2024 23:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 260 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-013071 · form4-05132024_110543.xml · derivative · entry 4 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,582 Underlying: Common Stock · 260 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · derivative.exercise_date: The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on August 14, 2021. Read SEC document |
| May 09, 2024 Filed May 13, 2024 23:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 260 | $25.06 | $6,515.50 |
DisclosureSEC source: 0001415889-24-013071 · form4-05132024_110543.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.155. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 09, 2024 Filed May 13, 2024 23:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 260 | $2.48 | $644.80 |
DisclosureSEC source: 0001415889-24-013071 · form4-05132024_110543.xml · nonDerivative · entry 1 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| May 06, 2024 Filed May 9, 2024 00:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,875 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001415889-24-012652 · form4-05092024_120559.xml · derivative · entry 4 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,842 Underlying: Common Stock · 4,875 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · derivative.exercise_date: The option, originally for 75,620 shares, vests in 48 equal monthly installments beginning on August 14, 2021. Read SEC document |
| May 06, 2024 Filed May 9, 2024 00:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,875 | $22.72 | $110,769.26 |
DisclosureSEC source: 0001415889-24-012652 · form4-05092024_120559.xml · nonDerivative · entry 2 Patel Anish · CIK 0001967163 · CHIEF OPERATING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.295 to $22.9429. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.